Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients

详细信息    查看全文

• 作者：Iedan R.N. Verly^a ; ^b ; ^e ; André ; B.P. van Kuilenburg^b ; Nico G.G.M. Abeling^b ; Susan M.I. Goorden^b ; Marta Fiocco^c ; ^d ; Fré ; dé ; ric M. Vaz^b ; Max M. van Noesel^e ; ^h ; C. Michel Zwaan^f ; GertJan L. Kaspers^g ; Johannes H.M. Merks^a ; Huib N. Caron^a ; Godelieve A.M. Tytgat^a ; ^e ; ^{G.A.M.Tytgat@prinsesmaximacentrum.nl}
• 关键词：Neuroblastoma ; Catecholamines ; Diagnostic sensitivity ; VMA and HVA negative ; MIBG non-avid tumours
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：72
• 期：Complete
• 页码：235-243
• 全文大小：1209 K
• 卷排序：72

文摘

Eight catecholamine metabolites have a diagnostic sensitivity of 95%; VMA and HVA have a diagnostic sensitivity of 84%. Normetanephrine is the most sensitive marker for neuroblastoma (NBL) diagnostics (89%). 3-methoxytyramine correlates the best with NBL high-risk features. Twenty-nine percent of the VMA and HVA non-excreting patients have a stage IV disease. Metaiodobenzylguanidine non-avid tumours excrete VMA and HVA in 33%, while other metabolites excrete in 89%.